ARHGEF2 and head and neck cancer: The clinical relevance of the GEF-H1 immune pathway is supported by our TCGA analysis, which shows a significant association of CD8A to the GEF-H1 immune gene signature in patients with melanoma, head and neck cancer, and uterine cancer.